Proper name: Esomeprazole Drug Developer: AstraZeneca plc Location:London, UK Website: www.astrazeneca.com Indication(s): Gastroesophageal reflux disease (GERD), for the healing of erosive esophagitis, and for the treatment of heartburn and other GERD symptoms Approval Date: 2001 2007 Revenue: $5.216 billion Percentage of AstraZeneca's Total Revenue: 17.65 percent Nexium is derived from Prilosec, AstraZeneca plc's original purple pill for heartburn. Both drugs are protein-pump inhibitors
Proper name: Salmeterol xinafoate/fluticasone propionate Drug Developer: GlaxoSmithKline plc Location:Brentford, UK Website: www.gsk.com Indication(s): Asthma and chronic obstructive pulmonary disease Approval Date: 1998 2007 Revenue: $6.998 billion Percentage of GlaxoSmithKline's Total Revenue: 15.51 percent Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the U.S. About 600 million people worldwide suffer from the disease, and an estimated 3 million
Proper name: Clopidogrel Drug Developer: Sanofi-Aventis and Bristol-Myers Squibb Co. Location:Paris, France, and New York, New York Website: www.sanofi-aventis.com and www.bms.com Indication(s): Protection against heart attacks and strokes, peripheral arterial disease and acute coronary syndrome Approval Date: 1997 2007 Revenue: Bristol-Myers Squibb: $4.755 billion Sanofi-Aventis: $3.805 billion Total: $8.56 billion Percentage of Bristol-Myers Squibb's Total Revenue: 24.58 percent
Proper name: Atorvastatin Drug Developer: Pfizer Inc. Location:New York, New York Website: www.pfizer.com Indication(s): High cholesterol Approval Date: 1996 2007 Revenue: $12.7 billion Percentage of Pfizer's Total Revenue: 26.12 percent Sales of Pfizer Inc.'s Lipitor decreased by $166 million from 2006, but it still held its place as the top-selling pharmaceutical, with more than $4 billion separating it from No. 2 on the list. With $12.7 billion in 2007 sales, it accounted for 26.12
Proper name: Recombinant Factor VIII Type: Antihemophilic Developer: Bayer HealthCare AG Location: Pittsburgh, Pennsylvania Web address: www.bayerhealthcare.com Indication(s): To treat or prevent bleeding in patients with hemophilia A Approval Date: February 1993; Kogenate FS approved in June 2000 2007 Revenue: $1.262 billion Percentage of Bayer's Total Revenue: 2.45 percent About Kogenate Bayer introduced its first Factor VIII in the early 1970s, and in February 1993, Bayer company
Proper name: Filgrastim Type: Anticancer, anti-infective Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): For the treatment of chemotherapy-induced neutropenia, for bone marrow transplant accompanied by neutropenia, bone marrow transplant engraftment or failure, mobilization of autologous peripheral blood progenitor cells after chemotherapy and severe chronic neutropenia Approval Date: February 1991 2007 Revenue: $1.277 billion
Proper name: Cetuxima Type: Anticancer Drug Developer: ImClone Systems Inc. Location: New York, New York Website: www.imclone.com Indication(s): Colorectal cancer that has spread to other parts of the body in patients whose tumors express an epidermal growth factor receptor (EGFR); in combination with radiation therapy for head and neck cancer Approval Date: February 2004 2007 Revenue: $1.430 billion Percentage of ImClone Systems' Total Revenue: 242 percent About Erbitux Cancer cells
Proper name: Insulin lispro Type: Insulin diabetes therapeutic Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For quick-response mealtime management of hyperglycemia in patients with diabetes mellitus Approval Date: June 1996 2007 Revenue: $1.475 billion Percentage of Eli Lilly's Total Revenue: 7.92 percent About Humalog Humalog is an insulin analog that is indicated for the treatment of patients with diabetes mellitus for the
Proper name: Interferon beta-1b Type: Autoimmune drug Drug Developer: Bayer Schering Pharma Location: Emeryville, California Website: www.bayerhealthcare.com. Indication(s): For the treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations Approval Date: August 1993 2007 Revenue: $1.586 billion Percentage of Bayer Schering's Total Revenue: 3.15 percent Multiple Sclerosis It's a disease that afflicts those from colder climates more than
Proper name: Emtricitabine and tenofovir disoproxil fumarate Type: Anti-HIV Developer: Gilead Sciences Inc. Location: Foster City, California Web address: www.gilead.com Indication(s): In combination with other antiretroviral agents for the treatment of HIV-1 infection Approval Date: August 2004 2007 Revenue: $1.589 billion Percentage of Gilead's Total Revenue: 37.57 percent About HIV/AIDS Human immunodeficiency virus (HIV) is the virus that causes AIDS (Acquired Immunodeficiency
Proper name: Peginterferon alfa-2a Type: Anti-viral Drug Developer: F. Hoffmann-La Roche Ltd. Location: Basel, Switzerland Website: www.roche.com Indication(s): For the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease, and for the treatment of adults with hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation. Approval Date: October 2002 2007 Revenue: $1.623 billion Percentage of Roche's Total
Proper name: Glatiramer acetate injection Type: Autoimmune drug Drug Developer: Teva Neuroscience Inc. Location: Kansas City, Missouri Website: www.tevaneuroscience.com Indication(s): For the reduction of relapses in relapsing-remitting multiple sclerosis Approval Date: December 1996 2007 Revenue: $1.713 billion Percentage of Teva's Total Revenue: 18.21 percent About Copaxone Copaxone is derived from amino acid proteins, making it a biotech drug, but it also relies heavily on chemical
Proper name: Interferon beta-1a Type: Autoimmune disease drug Drug Developer: Biogen Idec Inc. Location: Cambridge, Massachusetts Website: www.biogenidec.com Indication(s): Multiple sclerosis Approval Date: May 1996 2007 Revenue: $1.87 billion Percentage of Biogen Idec's Total Revenue: 59 percent Multiple Sclerosis Statistics Multiple sclerosis (MS) is an autoimmune disorder that affects the central nervous system (CNS). MS can be mild or strong and rapidly incapacitating. It can also
Proper name: Interferon beta-1a Type: Multiple sclerosis therapeutic Developer: Merck Serono SA Location: Geneva, Switzerland Web address: www.serono.com Indication(s): For interferon-specific disease modification in the treatment of relapsing multiple sclerosis to slow the development of physical disability and to decrease the frequency of exacerbations Approval Date: March 2002 2007 Revenue: $1.912 billion Percentage of Merck KGaA's Total Revenue: 17.03 percent About Rebif Rebif is
Proper name: Oseltamivir Type: Antiviral Developer: Roche Inc. Location: Nutley, New Jersey Web address: www.roche.com Indication(s): To prevent influenza (types A and B) and reduce disease symptoms immediately following exposure, in humans one year and older. Also, preventive and therapeutic agent against avian influenza (bird flu). Approval Date: October 1999 2007 Revenue: $2.067 billion Percentage of Roche's Total Revenue: 5.67 percent of Roche Group revenue Tamiflu and Influenza
Proper name: Pneumococcal polysaccharide vaccine Type: Vaccine Drug Developer: Wyeth Location: Madison, New Jersey Website: www.wyeth.com Indication(s): Prevention of diseases caused by Streptococcus pneumoniae (pneumococcus) Approval Date: February 2000 2007 Revenue: $2.439 billion Percentage of Wyeth's Total Revenue: 10.89 percent S. pneumoniae Diseases caused by Streptococcus pneumoniae (pneumococcus) include pneumonia, meningitis, ear infections and sinus infections. Even though
Proper name: Epoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): For the treatment of anemia in patients with chronic renal failure who are on dialysis Approval Date: June 1989 2007 Revenue: $2.489 billion Percentage of Amgen's Total Revenue: 16.85 percent Dialysis Treatment Indication Epogen is administered in end-stage indications that require somewhat severe therapies. Patients with end-stage renal
Proper name: Epoetin alpha Type: Antianemic Drug Developer: Ortho Biotech Products LP Location: Bridgewater, New Jersey Website: www.orthobiotech.com Indication(s): Eprex (outside the U.S.): To treat anemia associated with kidney disease by stimulating bone marrow to produce more red blood cells; to treat anemia and reduce the need for a blood transfusion for patients receiving chemotherapy for solid tumors, malignant lymphoma or multiple myeloma; as an alternative to a blood transfusion in
Proper name: Docetaxel Type: Anticancer Drug Developer: Sanofi-Aventis Location: Paris, France Website: www.sanofi-aventis.com Indication(s): For the treatment of locally advanced or metastatic breast cancer after failure of prior anthracycline chemotherapy; locally advanced or metastatic non-small-cell lung cancer (NSCLC); first-line therapy in combination with cisplatin for unresectable, locally advanced or metastatic NSCLC; hormone-refractory metastatic prostate cancer; in combination
Proper name: Esomeprazole Drug Developer: AstraZeneca plc Location:London, UK Website: www.astrazeneca.com Indication(s): Gastroesophageal reflux disease (GERD), for the healing of erosive esophagitis, and for the treatment of heartburn and other GERD symptoms Approval Date: 2001 2007 Revenue: $5.216 billion Percentage of AstraZeneca's Total Revenue: 17.65 percent Nexium is derived from Prilosec, AstraZeneca plc's original purple pill for heartburn. Both drugs are protein-pump inhibitors